Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Babini, G. S.
Right arrow Articles by Livermore, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Babini, G. S.
Right arrow Articles by Livermore, D. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy, Vol 41, 115-118, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy

ORIGINAL ARTICLES

Unusual tazobactam-sensitive AmpC beta-lactamase from two Escherichia coli isolates

GS Babini, F Danel, SD Munro, PA Micklesen and DM Livermore
Department of Medical Microbiology, St Bartholomew's, London, UK.

Two Escherichia coli isolates were studied. MIC patterns and hydrolysis assays suggested that they hyperproduced AmpC beta-lactamase, but synergy between ceftazidime and tazobactam was greater than between ceftazidime and Ro 48-1256, whereas the converse pattern is typical of AmpC hyperproducers. Studies with purified beta-lactamase from one of the isolates confirmed that tazobactam was a 100-fold stronger inhibitor than for the classical E. coli AmpC enzyme. Moreover, in contrast to typical AmpC types, the new enzyme had greater affinity for cephaloridine than for benzylpenicillin.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
G. A. Jacoby
AmpC {beta}-Lactamases
Clin. Microbiol. Rev., January 1, 2009; 22(1): 161 - 182.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
K. Nasim, S. Elsayed, J. D. D. Pitout, J. Conly, D. L. Church, and D. B. Gregson
New Method for Laboratory Detection of AmpC {beta}-Lactamases in Escherichia coli and Klebsiella pneumoniae
J. Clin. Microbiol., October 1, 2004; 42(10): 4799 - 4802.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
Y. Doi, J.-i. Wachino, M. Ishiguro, H. Kurokawa, K. Yamane, N. Shibata, K. Shibayama, K. Yokoyama, H. Kato, T. Yagi, et al.
Inhibitor-Sensitive AmpC {beta}-Lactamase Variant Produced by an Escherichia coli Clinical Isolate Resistant to Oxyiminocephalosporins and Cephamycins
Antimicrob. Agents Chemother., July 1, 2004; 48(7): 2652 - 2658.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. Philippon, G. Arlet, and G. A. Jacoby
Plasmid-Determined AmpC-Type {beta}-Lactamases
Antimicrob. Agents Chemother., January 1, 2002; 46(1): 1 - 11.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.